Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis

Pink, Daniel; Richter, Stephan; Gerdes, Sebastian; Andreou, Dimosthenis; Tunn, Per‐Ulf; Busemann, Christoph; Ehninger, Gerhard; Reichardt, Peter; Schüler, Markus

doi:10.1159/000362602

Cited by 42 publications

(50 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly poor survival rates for patients with metastatic ES were reported in an analysis of cases in the Surveillance, Epidemiology, and End Results database . Doxorubicin‐based regimens and gemcitabine combined with docetaxel have limited activity in ES, and more effective drugs are needed . The response of SFT to dasatinib was worse than the results in previous reports of treatment with temozolomide and bevacizumab or sunitinib with the Choi response criteria .…”

Section: Discussionmentioning

confidence: 63%

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Schuetze

Bolejack

Choy

et al. 2016

Cancer

107

View full text Add to dashboard Cite

BACKGROUND: Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed. METHODS: The 5 listed subtypes were enrolled into a single indolent sarcoma cohort in a phase 2 study of dasatinib using a Bayesian continuous monitoring rule for enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) rate according to the Choi criteria with a target of 50%. Cross-sectional imaging was performed before the start of treatment, every 2 months for 6 months, and then every 3 months during treatment. The 2-and 5-year survival rates were determined. RESULTS: One hundred sixteen patients were enrolled within 45 months, and 109 began treatment with dasatinib. The 6-month PFS rate and the median PFS were 48% and 5.8 months, respectively. The PFS rate at 6 months was highest with ASPS (62%) and lowest with SFT (30%). More than 10% of the patients with ASPS, CS, or chordoma had stable disease for more than 1 year. Collectively, for all 5 subtypes, the 2-and 5-year overall survival rates were 44% and 13%, respectively. An objective response was observed in 18% of the patients with CS or chordoma. CONCLUSIONS: Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more than 50% of the patients in this trial according to the Choi tumor response criteria. An objective tumor response and prolonged stable disease was observed in >10% of patients with CS or chordoma. Cancer 2017;123:90-7.

show abstract

Section: Discussionmentioning

confidence: 63%

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Schuetze

Bolejack

Choy

et al. 2016

Cancer

107

View full text Add to dashboard Cite

show abstract

“…However, in all patients, a diagnosis of ES was confirmed by expert pediatric reference pathologists according to the WHO criteria . This tumor is reported to be chemosensitive with a response rate to anthracycline‐based regimes of 22% . In our series, 35% of patients with LD, 33% with RD, and 40% with MD responded to CHT.…”

Section: Discussionmentioning

confidence: 99%

“…This tumor appears to be chemosensitive with a response rate to anthracycline‐based regimes of 22%. However, the reported progression‐free survival rates (PFS) are poor at six months . Targeted therapies with anti‐IGF‐1R recombinant monoclonal antibody cixutumumab in combination with doxorubicin or dasatinib are about to be evaluated in current clinical trials and first results have been published for adults .…”

Section: Introductionmentioning

confidence: 99%

Epithelioid sarcoma in children, adolescents, and young adults: Localized, primary metastatic and relapsed disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry

Sparber‐Sauer

Kościelniak

Vokuhl

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Epithelioid sarcoma (ES) is a rare malignant soft‐tissue tumor. Little is known about the optimal treatment of primary localized (LD), metastatic (MD), and relapsed disease (RD). Methods Characteristics, treatment, and outcome of 67 patients registered within the Cooperative Weichteilsarkom Studiengruppe CWS‐81, ‐86, ‐91, ‐96, ‐2002P trials and the registry SoTiSaR were analyzed (1981–2016). Results The median age was 14 years (range, 0.7–26.9); 53 patients had localized disease (LD) and 14 metastatic disease (MD). A total of 58 of 67 patients were treated with primary resection. Resection was microscopically complete (R0) in 35, microscopically incomplete (R1) in 12, macroscopically incomplete (R2) in 20 patients. Radiotherapy (RT) was administered to 33 of 67 patients and 49 of 67 patients received chemotherapy (CHT). Complete remission (CR) was achieved in 45 of 53 (85%) patients with LD. Twenty‐seven of 53 patients relapsed after a median time of 0.9 years (range, 0.1–2.3). Relapse therapy consisted of resection (n = 19/27), RT (n = 10/27), CHT (n = 12/27), and limb perfusion (n = 3/27). The five‐year event‐free survival and overall survival of patients with LD, MD, and RD was 35% (± 12, CI 95%) and 58% (± 14, CI 95%), 7% (± 14, CI 95%), and 9% (± 16, CI 95%), 24% (± 17, CI 95%), and 40% (± 20, CI 95%), respectively. Tumor size, IRS group, tumor invasiveness, nodal status, and best resection correlated with a favorable prognosis in patients with LD while best resection was the only significant factor in patients with RD. Conclusions Complete tumor resection correlates with long‐term survival in patients with ES.

show abstract

“…6,64,70,71 Smaller studies suggest GD has activity in other less common STS subtypes including angiosarcoma and epithelioid sarcoma. 72,73 …”

Section: Gemcitabine and Docetaxelmentioning

confidence: 99%

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

Tseng

2017

Ther Adv Med Oncol

View full text Add to dashboard Cite

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefit beyond the first-line setting; across all high-grade STS subtypes, median overall survival remains approximately 12–18 months for advanced metastatic disease. The development of targeted therapies has led to recent US Food and Drug Administration approval of four new treatments for high-grade STS in the advanced metastatic setting. Among these, olaratumab is most notable for its improvement in overall survival for patients with anthracycline-naïve disease. Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.

show abstract

Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis

Cited by 42 publications

References 24 publications

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

Epithelioid sarcoma in children, adolescents, and young adults: Localized, primary metastatic and relapsed disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

Contact Info

Product

Resources

About